• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Wednesday, March 29, 2023
McLennan County News
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home Technology Gaming

Big Tech, Chipmakers Power Nasdaq As Omicron Worries Subside – Reuters

big-tech,-chipmakers-power-nasdaq-as-omicron-worries-subside-–-reuters
Share on FacebookShare on Twitter

A street sign for Wall Street is seen outside the New York Stock Exchange (NYSE) in New York City, New York, U.S., July 19, 2021. REUTERS/Andrew Kelly

Register now for FREE unlimited access to reuters.com
  • Intel jumps on plans to list self-driving car unit
  • Travel shares join rebound
  • Merck slips on pausing enrollment in HIV-1 trials
  • Indexes up: Dow 1.3%, S&P 1.7%, Nasdaq 2.4%

Dec 7 (Reuters) – The Nasdaq rallied more than 2% on Tuesday as technology firms bounced back on easing concerns around the Omicron variant, while Intel jumped after plans to take its self-driving car unit public.

Investors cheered the chip giant’s (INTC.O) decision to list Mobileye in the United States in mid-2022, sending its shares 5.0% higher. The Philadelphia SE Semiconductor index (.SOX) surged 3.5%, bouncing off a near one-month low hit in the previous session.

Ten of 11 major S&P sectors advanced in early trading, with the information technology (.SPLRCT) sector, which houses companies like Visa Inc (V.N), Mastercard Inc (M.N), Salesforce.com (CRM.N) and Apple Inc (AAPL.O), gaining 2.5%.

Register now for FREE unlimited access to reuters.com

Wall Street’s main indexes closed higher on Monday as optimistic comments from a top U.S. official about Omicron encouraged investors. The CBOE volatility index, too, eased from a 10-month high hit last week, when fears around the new virus strain and the Federal Reserve’s hawkish comments rattled investors.

“With yesterday’s rally, investors are starting to get their minds around the fact that the Fed is likely tapering for the right reasons,” said Art Hogan, chief market strategist at National Securities in New York.

“And the second thing is that there’s been a diminishing economic impact of every new variant of the coronavirus since the pandemic began.”

High-flying growth names including Nvidia (NVDA.O) and Tesla (TSLA.O) were battered in recent days as investors rotated into sectors like energy, banks on expectations that the Federal Reserve will tighten monetary policy quicker to curb surging inflation.

U.S. bank executives raised concerns about the impact of a sustained period of higher inflation, adding to pressure on the Fed to accelerate plans to slow down the pace of its asset purchases. read more

Other mega-cap tech stocks Google-owner Alphabet (GOOGL.O), Microsoft (MSFT.O) and Amazon (AMZN.O) gained between 1.9% and 2.1%, helping the Nasdaq outperform its peers.

Tesla Inc (TSLA.O) added 3.4% after dropping into bear market territory, or 20% off its record high close, on an intraday basis on Monday.

At 9:52 a.m. ET, the Dow Jones Industrial Average (.DJI) was up 439.49 points, or 1.25%, at 35,666.52, the S&P 500 (.SPX) was up 78.04 points, or 1.70%, at 4,669.71, and the Nasdaq Composite (.IXIC) was up 361.97 points, or 2.38%, at 15,587.12.

Shares of Vir Biotechnology (VIR.O) jumped 3.9% after British drugmaker GSK (GSK.L) said an antibody-based COVID-19 therapy it is developing with Vir is effective against all mutations of the Omicron variant. read more

Travel shares continued the momentum, with the S&P 1500 Airlines (.SPCOMAIR) and the S&P 1500 Hotels, Restaurant and Leisure (.SPCOMHRL) indexes rising 1.7% and 2.2% respectively.

American Airlines (AAL.O) added 2.4% after the carrier announced the retirement of Chief Executive Officer Doug Parker. read more

Merck & Co (MRK.N) fell 1.9% as Guggenheim downgraded the stock to “neutral” from “buy” after the drugmaker paused enrollment in two late-stage clinical trials testing its experimental drug for treatment and prevention of HIV-1.

Advancing issues outnumbered decliners by a 8.59-to-1 ratio on the NYSE and a 6.42-to-1 ratio on the Nasdaq.

The S&P index recorded 25 new 52-week highs and no new low, while the Nasdaq recorded 25 new highs and 17 new lows.

Register now for FREE unlimited access to reuters.com

Reporting by Sruthi Shankar, Devik Jain and Shreyashi Sanyal in Bengaluru; Editing by Saumyadeb Chakrabarty and Maju Samuel

Our Standards: The Thomson Reuters Trust Principles.

McLennan County News

© 2021 McLennan County News Online

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 McLennan County News Online

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT